Sangamo Therapeutics, INC 8-K filings

Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection and its Nasdaq delisting request has been denied, leading to trading on the OTCQB.

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and its stock now trades on the OTCID Basic Market, while a Nasdaq delisting appeal is pending.

Sangamo Therapeutics reported first quarter 2026 financial results, including a net loss of $31.0 million, while also announcing its common stock was delisted from Nasdaq and began trading on the OTCQB Venture Market.

Sangamo Therapeutics has received a delisting notice from Nasdaq due to a sustained low stock bid price and will transition to the OTCQB Venture Market.

Sangamo reported a wider FY25 net loss as it advances a rolling BLA for its Fabry gene therapy, but warned of severe funding risk with cash runway only into Q3 2026.

Sangamo Therapeutics, Inc. announced an underwritten public offering of common stock and warrants, expected to generate approximately $25.0 million in gross proceeds.

Sangamo Therapeutics announced positive clinical data from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec, a gene therapy for Fabry disease, supporting an Accelerated Approval pathway.

Sangamo Therapeutics announced preliminary cash and cash equivalents of $20.9 million as of December 31, 2025, alongside the departure of its principal financial officer and the appointment of an interim CFO.

Sangamo Therapeutics announced its third quarter 2025 financial results and provided updates on its Fabry disease and neurology pipeline programs, including progress towards regulatory submissions.

Sangamo Therapeutics, Inc. received a 180-day extension from Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement.

Sangamo Therapeutics announced the appointment of Nikunj Jain as Principal Accounting Officer, effective October 1, 2025, following Prathyusha Duraibabu's transition to a part-time role.

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, will resign effective October 1, 2025, to join a private AI company, with an interim plan for continuity.

Sangamo Therapeutics announced updated positive clinical data from its Phase 1/2 STAAR study for isaralgagene civaparvovec, a gene therapy for Fabry disease, supporting its accelerated approval pathway.

Sangamo Therapeutics announced positive topline results from its registrational STAAR study for Fabry disease, alongside its second quarter 2025 financial results, highlighting progress in its neurology pipeline.

Sangamo Therapeutics announced highly positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a wholly owned investigational gene therapy for Fabry disease, demonstrating significant clinical benefits and a favorable safety profile.

Sangamo Therapeutics, Inc. announced that its stockholders approved an amendment to its 2018 Equity Incentive Plan, increasing the available shares for awards by 14 million, and re-elected all nine director nominees at its annual meeting on June 12, 2025.

Sangamo Therapeutics has entered into an underwriting agreement for a $23 million offering of common stock and warrants.

Sangamo Therapeutics received a notice from Nasdaq for failing to meet the minimum bid price requirement, potentially leading to delisting.

Sangamo Therapeutics announces advancements in its neurology pipeline, key licensing agreements, and financial results for the fourth quarter and full year 2024.

Sangamo Therapeutics reports updated clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease, showing sustained benefits and a potential accelerated approval pathway.

Pfizer has terminated its collaboration agreement with Sangamo Therapeutics for the development of giroctocogene fitelparvovec, a gene therapy for hemophilia A, effective April 21, 2025.

Sangamo Therapeutics has resolved a legal challenge regarding its share authorization and Pfizer presented positive Phase 3 trial data for a hemophilia A gene therapy co-developed with Sangamo.

Sangamo Therapeutics reports a clear regulatory pathway for its Fabry disease treatment, significant licensing revenue, and positive third-quarter financial results.

Sangamo Therapeutics is seeking court validation for a previously approved increase in authorized shares after a stockholder lawsuit challenged the voting process.

Sangamo Therapeutics reported a significant licensing agreement with Genentech, positive Phase 3 trial results for a partnered hemophilia A therapy, and encouraging data from its Fabry disease program, alongside its second quarter 2024 financial results.

Sangamo Therapeutics announced positive topline results from Pfizer's Phase 3 AFFINE trial for their hemophilia A gene therapy, giroctocogene fitelparvovec, showing significant reductions in bleeding rates.

Sangamo Therapeutics' stockholders approved amendments to the 2018 Equity Incentive Plan, increasing the number of shares available for issuance and incentive stock options, and also approved an increase in the total number of authorized shares of common stock.

Sangamo Therapeutics announced its first quarter 2024 financial results, highlighted by a $49.1 million net loss, and provided updates on its neurology-focused pipeline and recent business developments, including a $24 million capital raise.

Sangamo Therapeutics has been notified by Nasdaq that its stock price has fallen below the minimum required bid price of $1.00 per share for continued listing.

Sangamo Therapeutics has entered into a securities purchase agreement to raise approximately $24 million through a registered direct offering of common stock and warrants.